June 26, 2018 / 12:44 AM / 6 months ago

BRIEF-Everest Medicines unit buys License To Develop Novel FGFR4 Kinase Inhibitor

June 25 (Reuters) -

* EVEREST MEDICINES SUBSIDIARY ACQUIRES EXCLUSIVE WORLDWIDE LICENSE TO DEVELOP AND COMMERCIALIZE CLINICAL STAGE NOVEL FGFR4 KINASE INHIBITOR

* EVEREST MEDICINES- UNIT ENTERED LICENSING AGREEMENT TO DEVELOP NOVARTIS’ NOVEL FGFR4 (FIBROBLAST GROWTH FACTOR RECEPTOR 4) KINASE INHIBITOR, FGF401 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below